News

BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in Africa

MAINZ, Germany, June 9, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) will welcome its African partners for the first…

2 years ago

Baylor Scott & White Health and Contessa Announce Partnership to Create New Model of At-Home Care for Patients

Partnership will create a continuum of at-home care that encourages patient choice, reduces costs and improves outcomesDALLAS and NASHVILLE, Tenn.,…

2 years ago

Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market

DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has…

2 years ago

SciSparc’s Board of Directors Provides Strategic Decision

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on…

2 years ago

Amedisys Releases Inaugural Environmental, Social and Governance (ESG) Report

BATON ROUGE, La., June 09, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,…

2 years ago

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the…

2 years ago

Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been…

2 years ago

Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline…

2 years ago

Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa…

2 years ago

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage…

2 years ago